Silence Therapeutics (NASDAQ:SLN) Price Target Cut to $4.00 by Analysts at The Goldman Sachs Group

Silence Therapeutics (NASDAQ:SLN) had its price objective reduced by The Goldman Sachs Group from $6.00 to $4.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a “sell” rating on the stock. The Goldman Sachs Group’s price objective would indicate a potential downside of 4.76% from the company’s previous close.

Several other analysts also recently weighed in on SLN. HC Wainwright reiterated a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Wednesday, January 29th. Chardan Capital reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Silence Therapeutics in a research note on Tuesday, December 10th. BMO Capital Markets reissued an “outperform” rating on shares of Silence Therapeutics in a research note on Monday, December 2nd. Finally, William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $44.60.

Silence Therapeutics Price Performance

Shares of NASDAQ SLN opened at $4.20 on Tuesday. The company has a market capitalization of $125.71 million, a P/E ratio of -2.68 and a beta of 1.05. The company has a 50 day simple moving average of $5.58 and a 200-day simple moving average of $11.65. Silence Therapeutics has a 1 year low of $4.06 and a 1 year high of $27.72.

Institutional Investors Weigh In On Silence Therapeutics

Large investors have recently added to or reduced their stakes in the business. Eventide Asset Management LLC purchased a new stake in Silence Therapeutics in the 3rd quarter worth approximately $11,635,000. Parkman Healthcare Partners LLC lifted its holdings in shares of Silence Therapeutics by 71.8% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company’s stock valued at $9,051,000 after acquiring an additional 208,029 shares in the last quarter. Point72 Asset Management L.P. lifted its stake in shares of Silence Therapeutics by 219.3% during the third quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company’s stock worth $8,505,000 after purchasing an additional 321,300 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in Silence Therapeutics by 32.8% in the 3rd quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock worth $19,798,000 after acquiring an additional 268,250 shares during the period. Finally, Verition Fund Management LLC purchased a new position in shares of Silence Therapeutics in the third quarter valued at $207,000. 98.73% of the stock is owned by institutional investors and hedge funds.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.